Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 8/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24449893 | 0.88 | HSP90AA1 (0.45) | RAB9ASMN1; SMN2L3MBTL1NPC1KMT2A | |
| SCHEMBL24448756 | 0.73 | MEN1 (0.45) | RAB9ASMN1; SMN2L3MBTL1NPC1KMT2A | |
| SCHEMBL25587168 | 0.72 | RAB9A (0.42) | RAB9ASMN1; SMN2DUSP3L3MBTL1NPC1 | |
| SCHEMBL25946918 | 0.70 | KMT2A (0.38) | RAB9ASMN1; SMN2DUSP3L3MBTL1NPC1 | |
| SCHEMBL24344259 | 0.69 | KLKB1 (0.48) | RAB9ASMN1; SMN2DUSP3L3MBTL1KMT2A | |
| SCHEMBL26800277 | 0.69 | HSP90AA1 (0.38) | RAB9ASMN1; SMN2L3MBTL1NPC1KMT2A | |
| SCHEMBL24448755 | 0.68 | AADAT (0.40) | RAB9ASMN1; SMN2L3MBTL1NPC1KMT2A | |
| SCHEMBL19170547 | 0.67 | RAB9A (0.50) | RAB9ASMN1; SMN2DUSP3L3MBTL1NPC1 | |
| SCHEMBL2612033 | 0.65 | CYP1A2 (0.52) | — | |
| SCHEMBL30739115 | 0.65 | PARP1 (0.53) | L3MBTL1KMT2AKLKB1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11685732-B2 | MYST family histone acetyltransferase inhibitors | Epizyme, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | EP300, KAT2A, KAT6A | RAB9A 2422/4885SMN1; SMN2 3017/4885DUSP3 1161/4885 |
| US-11685732-B2 | MYST family histone acetyltransferase inhibitors | EP300, KAT2A, KAT6A | RAB9A 2422/4885SMN1; SMN2 3017/4885DUSP3 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.